GlassScriptPhysician profile
Muhammad Haris
NPI 1073043279
$4,974.14
in general payments reported to CMS, 2019-2025
25 companies · $1,992 in 2025
The $1,992 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $613 · 2023: $666 · 2024: $1,704 · 2025: $1,992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,361.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,212.45 | 2023-2025 | |
| Ardelyx, INC. | $503.65 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $489.20 | 2023-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $448.79 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $298.81 | 2023-2025 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $246.82 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $246.81 | 2022-2023 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.78 | 2024-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $200.59 | 2023-2025 | Vemlidy |
| Aimmune Therapeutics, INC. | $136.26 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $128.41 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $122.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Astrazeneca Pharmaceuticals LP | $119.27 | 2022 | |
| Evoke Pharma, INC. | $82.33 | 2024-2025 | |
| Daiichi Sankyo INC. | $75.67 | 2023-2024 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $70.99 | 2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $66.40 | 2024 | |
| Intercept Pharmaceuticals, INC. | $59.28 | 2024-2025 | |
| Pfizer INC. | $55.47 | 2025 | |
| Phathom Pharmaceuticals, INC. | $53.50 | 2024 | Voquezna |
| Medtronic, INC. | $44.36 | 2025 | Spiderfx |
| Ipsen Biopharmaceuticals, INC | $20.55 | 2025 | Iqirvo |
| Organon LLC | $17.91 | 2023 | Hadlima |
| Nestle Healthcare Nutrition INC. | $16.55 | 2023 | |
| Ferring Pharmaceuticals INC. | $14.97 | 2025 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Haris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.